Source: GlobalData
Lantheus to strengthen position in nuclear imaging agents with recent acquisitions, says GlobalData
Posted in Medical Devices
The demand for nuclear imaging agents is expected to grow significantly, driven by an aging population and advancements in imaging technologies. The industry is shifting toward more targeted, patient-specific solutions, particularly in neuroimaging and oncology, where early detection and personalized treatment are critical. Lantheus’ acquisition of Life Molecular Imaging and Evergreen Theragnostics will strengthen its position in this evolving landscape and expand its capabilities in key diagnostic areas, according to GlobalData, a leading data and analytics company.
Ashley Clarke, Senior Medical Analyst at GlobalData, comments: “The nuclear imaging industry is increasingly driven by the demand for advanced neuroimaging agents in Alzheimer’s disease and targeted oncology solutions for more precise cancer detection and treatment. These innovations are helping drive a more patient-specific approach to disease management. The competitive landscape is evolving quickly, with multiple companies competing to establish leadership in this space.”
Lantheus’ acquisition of Life Molecular Imaging includes Neuraceq, an FDA-approved PET agent for detecting β-amyloid plaques in Alzheimer’s disease, and ADvance (PI-2620), a tau PET imaging agent in late-stage clinical development. These additions complement its existing pipeline, which includes β-amyloid agent NAV-4694, acquired from Meilleur Technologies in 2024, and tau agent MK-6240, acquired from Cerveau Technologies in 2023.
Clarke adds: “Lantheus is building a robust neuroimaging portfolio that strategically balances short-term revenue growth with long-term innovation in Alzheimer’s diagnostics. Neuraceq provides immediate competition with established products such as Eli Lilly’s Amyvid and GE Healthcare’s Vizamyl. Meanwhile, the pipeline potential of ADvance positions the company as a strong player in the quickly growing tau-based imaging market.”
Beyond neuroimaging, Lantheus is expanding its presence in oncology. Lantheus has announced an agreement to acquire Evergreen Theragnostics, a radiopharmaceutical company specializing in the development and manufacturing of imaging agents for cancer diagnosis and treatment. This acquisition includes Octevy, a registrational-stage PET diagnostic agent targeting neuroendocrine tumors. Additionally, in mid-2024, the company licensed RM2 from Life Molecular Imaging, a theranostic agent that uses Lu-177 and Ga-68 to treat malignant tumors, including prostate, breast, and lung cancers.
The RM2 and Octevy additions build on Lantheus’ established oncology portfolio, which includes Pylarify, a leading PSMA-targeting imaging agent, and a range of pipeline products addressing prostate cancer, neuroendocrine tumors, and other solid tumors. The oncology imaging space is highly competitive, with companies such as Eli Lilly, GE Healthcare, Curium Pharma, and Novartis also developing targeted imaging and theranostic solutions.
Clarke concludes: “Looking ahead, nuclear imaging is set to become increasingly integrated with therapeutic applications. The next wave of innovation will likely introduce multi-targeted theranostics and agents with broader biomarker coverage, enhancing both diagnostic accuracy and therapeutic outcomes. As new imaging technologies emerge, companies that successfully align their portfolios with both clinical demand and market dynamics will be best positioned for long-term success.”